West Pharmaceutical Services, Inc. (NYSE:WST) has been given an average rating of “Hold” by the seven brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $106.00.

Several research firms have commented on WST. Stephens began coverage on West Pharmaceutical Services in a research report on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price objective on the stock. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. Wells Fargo & Company upped their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Bank of America lowered West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective on the stock. in a research report on Tuesday, October 17th. Finally, Jefferies Group upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and upped their price objective for the stock from $96.00 to $115.00 in a research report on Friday, September 15th.

In other news, CFO William J. Federici sold 21,000 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $99.01, for a total transaction of $2,079,210.00. Following the completion of the transaction, the chief financial officer now directly owns 190,493 shares of the company’s stock, valued at approximately $18,860,711.93. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.90% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of West Pharmaceutical Services by 0.3% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,735 shares of the medical instruments supplier’s stock worth $1,015,000 after buying an additional 34 shares during the period. Teacher Retirement System of Texas raised its stake in West Pharmaceutical Services by 0.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 5,867 shares of the medical instruments supplier’s stock valued at $555,000 after purchasing an additional 40 shares during the last quarter. Hillsdale Investment Management Inc. raised its stake in West Pharmaceutical Services by 0.7% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 12,080 shares of the medical instruments supplier’s stock valued at $1,142,000 after purchasing an additional 80 shares during the last quarter. Utah Retirement Systems raised its stake in West Pharmaceutical Services by 1.5% in the 2nd quarter. Utah Retirement Systems now owns 13,400 shares of the medical instruments supplier’s stock valued at $1,266,000 after purchasing an additional 200 shares during the last quarter. Finally, Commerce Bank raised its stake in West Pharmaceutical Services by 1.4% in the 2nd quarter. Commerce Bank now owns 15,765 shares of the medical instruments supplier’s stock valued at $1,490,000 after purchasing an additional 215 shares during the last quarter. 93.28% of the stock is owned by institutional investors and hedge funds.

Shares of West Pharmaceutical Services (NYSE WST) opened at $98.73 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87. West Pharmaceutical Services has a 52-week low of $77.97 and a 52-week high of $103.36. The company has a market capitalization of $7,370.00, a P/E ratio of 42.35, a price-to-earnings-growth ratio of 2.10 and a beta of 1.12.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.14. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The business had revenue of $398.20 million for the quarter, compared to analyst estimates of $386.02 million. During the same quarter in the prior year, the firm posted $0.53 EPS. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. sell-side analysts forecast that West Pharmaceutical Services will post 2.76 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “West Pharmaceutical Services, Inc. (WST) Receives Consensus Recommendation of “Hold” from Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/17/west-pharmaceutical-services-inc-wst-receives-consensus-recommendation-of-hold-from-analysts.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Analyst Recommendations for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.